Association of plasma potassium with mortality and end-stage kidney disease in patients with chronic kidney disease under nephrologist care - The NephroTest study

[1] Brenner BM(2001)Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy N Engl J Med 345 861-869

[2] Cooper ME(2011)Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials Eur Heart J 32 1493-1499

[3] de Zeeuw D(2001)The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes N Engl J Med 345 870-878

[4] Keane WF(2016)Association between Serum Potassium and Outcomes in Patients with Reduced Kidney Function Clin J Am Soc Nephrol 11 90-100

[5] Mitch WE(2004)Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system N Engl J Med 351 585-592

[6] Parving HH(2014)Time to retrieve the best benefits from renin angiotensin aldosterone system (RAAS) inhibition in heart failure patients with reduced ejection fraction: lessons from randomized controlled trials and registries Int J Cardiol 177 731-733

[7] Remuzzi G(2016)Emergency management of severe hyperkalemia: Guideline for best practice and opportunities for the future Pharmacol Res 113 585-591

[8] Snapinn SM(2016)New approaches to hyperkalemia in patients with indications for renin angiotensin aldosterone inhibitors: Considerations for trial design and regulatory approval Int J Cardiol 216 46-51

[9] Zhang Z(2012)Predictors of hyperkalemia and death in patients with cardiac and renal disease Am J Cardiol 109 1510-1513

[10] Shahinfar S(2014)Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF) Circ Heart Fail 7 51-58

[1] Brenner BM(2001)Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy N Engl J Med 345 861-869

[2] Cooper ME(2011)Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials Eur Heart J 32 1493-1499

[3] de Zeeuw D(2001)The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes N Engl J Med 345 870-878

[4] Keane WF(2016)Association between Serum Potassium and Outcomes in Patients with Reduced Kidney Function Clin J Am Soc Nephrol 11 90-100

[5] Mitch WE(2004)Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system N Engl J Med 351 585-592

[6] Parving HH(2014)Time to retrieve the best benefits from renin angiotensin aldosterone system (RAAS) inhibition in heart failure patients with reduced ejection fraction: lessons from randomized controlled trials and registries Int J Cardiol 177 731-733

[7] Remuzzi G(2016)Emergency management of severe hyperkalemia: Guideline for best practice and opportunities for the future Pharmacol Res 113 585-591

[8] Snapinn SM(2016)New approaches to hyperkalemia in patients with indications for renin angiotensin aldosterone inhibitors: Considerations for trial design and regulatory approval Int J Cardiol 216 46-51

[9] Zhang Z(2012)Predictors of hyperkalemia and death in patients with cardiac and renal disease Am J Cardiol 109 1510-1513

[10] Shahinfar S(2014)Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF) Circ Heart Fail 7 51-58